Supplementarymaterialtomanuscript

“ManagementofCKD-MBDinnon-dialysispatientsunderregularnephrologycare:a prospectivemulticenterstudy”

APPENDIX TABLE 1. Targets for PTH, phosphate and calcium pursued in each Center and their achievement at baseline and month 6 visit.

Target pursued in each Center / Target PTH (%) / Target Phosphate (%) / Target calcium (%)
Center / Patients / PTH / Phosphate / Calcium / Baseline / Month-6 / Baseline / Month-6 / Baseline / Month-6
1 / 42 / 35-70a/70-150b/150-300 c / 2.7-4.6 ab/3.5-5.5c / 8.4-9.5ab/8.6-10.3c / 26.2 / 31.0 / 88.1 / 92.9 / 73.8 / 59.5
2 / 48 / 35-70a/70-110b/150-300c / 2.7-4.6 ab/3.5-5.5c / 8.2-10.4 / 41.7 / 27.1 / 89.6 / 87.5 / 89.6 / 83.3
3 / 63 / 35-70a/70-150b/150-300c / 2.7-4.6 / 8.4-10.2 / 34.9 / 34.9 / 88.9 / 81.0 / 98.4 / 96.8
4 / 49 / 35-70a/70-110b/150-300c / 3.0-4.5 / 8.9-10.3 / 26.5 / 34.7 / 81.6 / 81.6 / 77.6 / 61.2
5 / 88 / <75 / <4.6 / 8.4-10.2 / 47.7 / 44.3 / 93.2 / 89.8 / 85.2 / 88.6
6 / 29 / 35-70a/70-110b/150-300c / 3.5-5.5 / 8.4-9.5 / 27.6 / 13.8 / 79.3 / 62.1 / 65.5 / 58.6
7 / 15 / 35-70a/70-110b/150-300c / <4.6 / 8.4-10.2 / 26.7 / 33.3 / 100.0 / 80.0 / 93.3 / 86.7
8 / 34 / 35-70a/70-110b/150-300c / 2.7-4.6 ab/3.5-5.5c / 8.4-9.5 / 23.5 / 29.4 / 100.0 / 91.2 / 70.6 / 79.4
9 / 54 / 35-70a/70-110b/150-300c / 2.7-4.6 ab/3.5-5.5c / 8.4-9.5 / 24.1 / 16.7 / 87.0 / 85.2 / 66.7 / 68.5
10 / 75 / 35-70a/70-110b/150-300c / 3.0-5.0 / 8.2-9.8 / 29.3 / 18.7 / 73.3 / 74.7 / 90.7 / 76.0*
11 / 34 / 70-300 / 2.7-5.5 / 8.4-10.5 / 61.8 / 76.5 / 97.1 / 91.2 / 85.2 / 88.2
12 / 7 / 35-70a/70-110b/150-300c / 3.5-5.5 / 8.2-9.8 / 14.3 / 14.3 / 85.7 / 71.4 / 100.0 / 100.0
13 / 13 / 35-70a/70-110b/150-300c / 2.5-4.5 / 8.4-9.5 / 7.7 / 30.8 / 53.8 / 53.8 / 53.8 / 53.8
14 / 47 / 35-70a/70-110b/150-300c / 2.7-4.6 ab/2.7-4.8c / 8.4-9.5 / 38.3 / 46.8 / 89.4 / 93.6 / 76.6 / 76.6
15 / 50 / <150a /<180b /<200c / <4.5ab/<4.8c / 8.8-10.2ab/9.0-10.2c / 74.0 / 74.0 / 96.0 / 98.0 / 66.0 / 50.0
16 / 32 / 50-270a,b/100-300c / 2.7-4.6 ab/3.5-5.5c / 8.2-9.5 / 75.0 / 71.9 / 84.4 / 93.8 / 90.6 / 78.1
17 / 18 / 35-70a/70-110b/150-300c / 2.7-4.6 ab/3.5-5.5c / 8.5-10 / 27.8 / 33.3 / 83.3 / 100.0 / 100.0 / 100.0
18 / 19 / 35-70a/70-110b/150-300c / 2.7-4.6 ab/3.5-5.5c / 8.8-10.4 / 31.6 / 31.6 / 89.5 / 89.5 / 100.0 / 100.0
19 / 10 / 35-70a/70-110b/150-300c / 2.7-4.6 ab/3.5-5.5c / 8.5-10.3 / 30.0 / 10.0 / 80.0 / 90.0 / 100.0 / 90.0

a, CKD Stage 3b, b, CKD Stage4; c, CKD Stage 5. * P<0.05 vs baseline.

1

APPENDIX TABLE 2. Clinical inertia for hyperparathyroidism, hyperphosphatemia and hypocalcemia according to targets followed in each center or those proposed by KDOQI and KDIGO guidelines.

Center-specific target / KDOQI target / KDIGO target / P
Hyperparathyrodism / 29.5 (24.6-34.4) / 31.8 (27.1-36.4) / 29.1 (25.0-33.2) / 0.646
Hyperphosphatemia / 54.3 (40.0-68.7) / 51.3 (35.6-67.0) / 67.1 (56.1-78.1) / 0.193
Hypocalcemia / 22.2 (8.6-35.8) / 20.0 (5.7-34.3) / 26.3 (12.3-40.3) / 0.819

Data are expressed as percent of patients inadequately treated (95% CI)

APPENDIX FIGURE 1. Flow chart of the study.

APPENDIX FIGURE 2. Treatment for CKD-MBD in patientsstratified for tertiles of calcium (panel A), phosphate (panel B) and PTH at baseline (panel C). LPD = low protein diet; Vit. D = any formof vitamin D.

1